ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Dr. Reddy's Laboratories is launching Perlecan Pharma, a drug development subsidiary that will commercialize drugs from the Indian firm that have completed Phase I clinical trials. Citigroup Venture Capital and private equity firm ICICI Venture are each contributing $22.5 million, and Dr. Reddy's is putting in $7.5 million. Perlecan will commercialize the drugs by licensing them to other companies or by partnering with other firms to complete clinical trials. Perlecan will initially acquire the rights to four Dr. Reddy's drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X